Gene · 10419
Papers3,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MS4322 is a selective protein arginine methyltransferase 5 degrader with antitumor effects in cervical cancer cells. | Oncol Rep | 2026 | 41891959 | PubTator, text mining | PubMed |
| PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. | Front Cell Dev Biol | 2026 | 41890907 | PubTator, text mining | PubMed |
| Quantitative DIA-MS Uncovers Functional Impact of SMARCA4 Knockdown in Group 3 Medulloblastoma. | J Proteome Res | 2026 | 41885501 | PubTator, text mining | PubMed |
| The cGAS-STING pathway in cancer: friend or foe. | Cell Death Dis | 2026 | 41881950 | PubTator, text mining | PubMed |
| Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard-of-Care and Emerging Therapeutic Strategies. | J Gastroenterol Hepatol | 2026 | 41877308 | PubTator, text mining | PubMed |
| Recent Advances in Targeted Therapies for Adult Gliomas. | Curr Neurol Neurosci Rep | 2026 | 41874881 | PubTator, text mining | PubMed |
| PRMT5/Sohlh2/Sirt1 Signaling Pathway in Vascular Endothelial Cells Modulates Lung Metastasis of Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | 41867089 | PubTator, text mining | PubMed |
| Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability. | Clin Transl Oncol | 2026 | 41866608 | PubTator, text mining | PubMed |
| Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade. | Proc Natl Acad Sci U S A | 2026 | 41860961 | PubTator, text mining | PubMed |
| FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | Cell Rep Med | 2026 | 41850237 | PubTator, text mining | PubMed |
| MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies. | Ann Oncol | 2026 | 41833902 | PubTator, text mining | PubMed |
| Acetylation-dependent nuclear translocation of EXOC4 regulates KU70 methylation to facilitate non-homologous end joining. | Cell Death Differ | 2026 | 41826730 | PubTator, text mining | PubMed |
| Coupled-enzyme assay for MTAP activity in biological samples. | Anal Biochem | 2026 | 41825704 | PubTator, text mining | PubMed |
| Gamma-aminobutyric acid transaminase mediates tumor suppression in renal cell carcinoma through the cGAS-STING-interferon-β axis. | Sci Rep | 2026 | 41813748 | PubTator, text mining | PubMed |
| Methylation of MATCAP by PRMT5 regulates microtubule detyrosination to ensure mitotic fidelity. | J Mol Cell Biol | 2026 | 41811993 | PubTator, text mining | PubMed |
| Inhibition of PRMT5 triggers synthetic lethality in ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation. | Mol Cancer | 2026 | 41803859 | PubTator, text mining | PubMed |
| Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC. | Cancer Sci | 2026 | 41801765 | PubTator, text mining | PubMed |
| Circular RNAs: Key Regulators of Tumor Metabolic Reprogramming and Clinical Translation. | Oncol Res | 2026 | 41799520 | PubTator, text mining | PubMed |
| Evaluation of Potential Therapeutic Targets for Bacterial Infectious Skin Diseases: A Proteome-Wide Mendelian Randomization Study. | Clin Cosmet Investig Dermatol | 2026 | 41799426 | PubTator, text mining | PubMed |
| The dual role of BRD9 in cancer: Mechanistic insights and therapeutic prospects. | iScience | 2026 | 41797932 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10419/papers?page=6